Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 7/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 6/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | RNMT | O43148 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.39 |
| ▸ | ATG7 | O95352 | 1/20 | 0.39 |
| ▸ | UBA7 | P41226 | 1/20 | 0.39 |
| ▸ | NAE1 | Q13564 | 1/20 | 0.39 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.39 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29772301 | 1.00 | METTL3 (0.46) | METTL3PRMT5ADORA1ADORA3SLC29A1 | |
| SCHEMBL29772282 | 0.89 | RXFP1 (0.37) | METTL3PRMT5ADORA1ADORA3ADORA2A | |
| SCHEMBL29772268 | 0.84 | PRMT5 (0.45) | METTL3PRMT5ADORA1ADORA3ADORA2A | |
| SCHEMBL23273841 | 0.84 | PRMT5 (0.45) | METTL3PRMT5ADORA1ADORA3ADORA2A | |
| SCHEMBL29772256 | 0.79 | PRMT5 (0.65) | METTL3PRMT5 | |
| SCHEMBL23273897 | 0.79 | PRMT5 (0.65) | METTL3PRMT5 | |
| SCHEMBL23312996 | 0.77 | ADORA3 (0.42) | METTL3PRMT5ADORA1ADORA3ADORA2A | |
| SCHEMBL29611607 | 0.74 | ADORA1 (0.54) | ADORA1ADORA3ADORA2A | |
| SCHEMBL27090409 | 0.74 | ADORA1 (0.54) | ADORA1ADORA3ADORA2A | |
| SCHEMBL23274005 | 0.74 | METTL3 (0.46) | METTL3PRMT5UBA6NAE1UBA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027361-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2021079196-A2 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC (US) | 2021-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027361-A1 | METTL3 MODULATORS | METTL3, METTL16, METTL14 | METTL3 1/4885PRMT5 69/4885ADORA1 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.